SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 14, 2017

Primary Completion Date

May 2, 2019

Study Completion Date

May 2, 2019

Conditions
Cancer
Interventions
DRUG

SC-004

Intravenous

DRUG

ABBV-181

Intravenous

Trial Locations (12)

35294

University of Alabama /ID# 202249, Birmingham

43210

The Ohio State University - Columbus /ID# 164089, Columbus

48202

Henry Ford Health System /ID# 202480, Detroit

60637

University of Chicago /ID# 200735, Chicago

63108

Washington University School /ID# 164091, St Louis

73104

Univ Oklahoma HSC /ID# 164090, Oklahoma City

77030

MD Anderson Cancer Center /ID# 200048, Houston

91010

City of Hope /ID# 202493, Duarte

72703-4005

Highlands Oncology Group /ID# 209165, Fayetteville

55905-0001

Mayo Clinic - Rochester /ID# 200732, Rochester

37203-1632

Tennessee Oncology-Nashville Centennial /ID# 164088, Nashville

84112-5500

Huntsman Cancer Institute /ID# 209164, Salt Lake City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY